[
    [
        {
            "time": "",
            "original_text": "仿制药价格体系加速重塑，药企迈向体系竞争时代|【光大医药·周报】",
            "features": {
                "keywords": [
                    "仿制药",
                    "价格体系",
                    "重塑",
                    "药企",
                    "体系竞争"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "仿制药价格体系加速重塑，药企迈向体系竞争时代|【光大医药·周报】",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "华龙投顾周观点第28期：科创开板迎改革利好，市场表现仍需观察",
            "features": {
                "keywords": [
                    "科创",
                    "开板",
                    "改革",
                    "利好",
                    "市场表现",
                    "观察"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华龙投顾周观点第28期：科创开板迎改革利好，市场表现仍需观察",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【国盛医药张金洋团队】周观点：详解2019Q2机构医药持仓，继续推荐2+X主线",
            "features": {
                "keywords": [
                    "国盛医药",
                    "机构持仓",
                    "2+X主线",
                    "推荐"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国盛医药张金洋团队】周观点：详解2019Q2机构医药持仓，继续推荐2+X主线",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "【东吴医药】周观点20190720：关注科创板南微医学和心脉医疗",
            "features": {
                "keywords": [
                    "东吴医药",
                    "科创板",
                    "南微医学",
                    "心脉医疗",
                    "关注"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "科技"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【东吴医药】周观点20190720：关注科创板南微医学和心脉医疗",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "“赢”战科创板｜首批上市股如何运行？稳中求进的概率偏大",
            "features": {
                "keywords": [
                    "科创板",
                    "首批上市股",
                    "运行",
                    "稳中求进",
                    "概率"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技",
                    "金融"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "“赢”战科创板｜首批上市股如何运行？稳中求进的概率偏大",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]